One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombacytopenia type II

Journal of Thoracic and Cardiovascular Surgery

Volumn 122, Issue 6, 2001, Pages 1254-1255

  Koster, Andreas ^a   Meyer, Oliver ^b   Fischer, Thomas ^a   Kukucka, Marian ^a   Krabatsch, Thomas ^a   Bauer, Matthias ^a   Kuppe, Herman ^a   Hetzer, Roland ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LEPIRUDIN; TIROFIBAN;

ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; HEPARINIZATION; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; THROMBOCYTE AGGLUTINATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0035783918     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2001.118271     Document Type: Article

References (5)

1. Poetzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343:515.
2. Harenberg J, Wang L, Hoffmann U, Huhle G, Feurig M. Improved laboratory confirmation of heparin-induced thrombocytopenia type II: Time course of antibodies and combination of antigen and biologic assays. Am J Clin Pathol. 2001;115:432-8.
3. Koster A, Kukucka M, Bach F, Meyer O, Fischer T, Mertzlufft F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb/IIIa antagonist tirofiban. Anesthesiology. 2001;94:245-51.
4. Mak KH, Kottke-Marchant K, Brooks LM, Topol EJ. In vitro effect of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia. Thromb Haemost. 1998;80:989-93.
5. Walenga JM, Jeske WP, Wallis DE, Bakhos M, Lewis BE, Leya F, et al. Clinical experience with combined treatment of thrombin inhibitors and GP IIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost. 1999;25(Suppl 1):77-81.